Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1191834

Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases


Javor, Eugen; Hauser, Goran; Skelin, Marko
Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases // JAMA. Journal of the American Medical Association, 327 (2022), 15; 1505-1505 doi:10.1001/jama.2022.2935 (međunarodna recenzija, pismo uredniku, znanstveni)


CROSBI ID: 1191834 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases

Autori
Javor, Eugen ; Hauser, Goran ; Skelin, Marko

Izvornik
JAMA. Journal of the American Medical Association (0098-7484) 327 (2022), 15; 1505-1505

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo uredniku, znanstveni

Ključne riječi
Therapeutic Drug Monitoring ; Inflammatory Bowel Disease

Sažetak
The recently published NOR-DRUM B trial demonstrated that proactive therapeutic drug monitoring (TDM) during maintenance therapy with infliximab was more effective in sustaining disease control in immune- mediated inflammatory diseases than treatment without TDM. We believe these results must be interpreted with caution. Prior trials that evaluated proactive TDM in inflammatory bowel disease (IBD) during maintenance infliximab therapy did not prove the effectiveness of this approach. Moreover, unintentional bias may have affected the primary outcome results of the NOR-DRUM B trial because data about infliximab levels and antidrug antibodies were not available for the standard therapy group at any time during the trial. Current guidelines for IBD conditionally recommend use of TDM during maintenance therapy in response to suboptimal disease control. Therapeutic drug monitoring may therefore drive the tailoring of IBD therapy (eg, escalation of infliximab therapy, introduction of an immunomodulator or another biologic drug).Moreover, as stated in the Limitations section, in this open-label trial the subjective assessment of disease worsening (defined by consensus between patient and physician) was also prone to bias. Therefore, it is not surprising that clinicians treating patients randomized to the standard therapy group may increase the infliximab dose if TDM results are unavailable. In this study, the infliximab dose was increased in 51.0% of patients in the standard therapy vs 31.6% of patients in the TDM group. We believe that failure to use TDM may have adversely affected the treatment and primary outcome results of some individuals with IBD randomized to the standard therapy group, and this should be noted as a study limitation.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Farmacija



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Rijeka,
Opća bolnica Šibenik,
Klinički bolnički centar Rijeka

Profili:

Avatar Url Goran Hauser (autor)

Avatar Url Marko Skelin (autor)

Poveznice na cjeloviti tekst rada:

doi jamanetwork.com pubmed.ncbi.nlm.nih.gov

Citiraj ovu publikaciju:

Javor, Eugen; Hauser, Goran; Skelin, Marko
Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases // JAMA. Journal of the American Medical Association, 327 (2022), 15; 1505-1505 doi:10.1001/jama.2022.2935 (međunarodna recenzija, pismo uredniku, znanstveni)
Javor, E., Hauser, G. & Skelin, M. (2022) Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases. JAMA. Journal of the American Medical Association, 327 (15), 1505-1505 doi:10.1001/jama.2022.2935.
@article{article, author = {Javor, Eugen and Hauser, Goran and Skelin, Marko}, year = {2022}, pages = {1505-1505}, DOI = {10.1001/jama.2022.2935}, keywords = {Therapeutic Drug Monitoring, Inflammatory Bowel Disease}, journal = {JAMA. Journal of the American Medical Association}, doi = {10.1001/jama.2022.2935}, volume = {327}, number = {15}, issn = {0098-7484}, title = {Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases}, keyword = {Therapeutic Drug Monitoring, Inflammatory Bowel Disease} }
@article{article, author = {Javor, Eugen and Hauser, Goran and Skelin, Marko}, year = {2022}, pages = {1505-1505}, DOI = {10.1001/jama.2022.2935}, keywords = {Therapeutic Drug Monitoring, Inflammatory Bowel Disease}, journal = {JAMA. Journal of the American Medical Association}, doi = {10.1001/jama.2022.2935}, volume = {327}, number = {15}, issn = {0098-7484}, title = {Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases}, keyword = {Therapeutic Drug Monitoring, Inflammatory Bowel Disease} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font